For an anti-receptor-based therapy decision, it is important to analyze whether more than 1% of BC cells express ER and PR hormone receptors and whether more than 10% of BC cells express higher levels of HER2 protein or show amplification of the HER2 gene [14,15]. This evidence concerns the gene PGR and breast cancer.